CXCL12 is known to transactivate EGFR [76], the axis CXCR4/CXCL12 is upregulated in HCC and participates in HCC cell proliferation [111] and BKT140 has been tested in clinical trials for the treatment of multiple myeloma [109]. This evidence concerns the gene CXCL12 and plasma cell myeloma.